
    
      The purpose of this study is to develop an accelerated infusion regimen that allows
      ofatumumab to be delivered in a safe manner while minimizing the time required administering
      the treatment. We hypothesize there will be fewer infusion-related reactions using the
      proposed dose-dense approach the first week before accelerating the rate of infusion.
    
  